In contrast, no clinical trial data is available so far for NSCLC treatment with PARPi, possibly due to the plenty of therapeutic methods for NSCLC and the very low incidence of BRCA1/2 germline mutations in NSCLC. Here, BRCA1 is linked to non-small cell lung carcinoma.